美沙拉嗪口服联合灌肠治疗溃疡性结肠炎的临床疗效

The clinical efficacy of mesalazine combined with oral enema in the treatment of ulcerative colitis(UC)

目的 探讨美沙拉嗪口服联合灌肠治疗方法在溃疡性结肠炎(UC)临床治疗中的应用效果。方法 将58例UC患者随机分为观察组(美沙拉嗪口服联合灌肠治疗)和对照组(美沙拉嗪口服治疗)各29例,观察两组患者治疗前后的血清炎性因子水平、症状改善情况,对比其治疗恢复效果。结果 与治疗前相比,两组患者治疗后的C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)等血清炎性因子水平显著降低(P<0.05),且观察组CRP水平[(6.51±0.43)mg/L vs.(7.74±0.57)mg/L,t=9.277]、TNF-α水平[(0.24±0.09)μg/L vs.(0.37±0.13)μg/L,t=4.428]明显较对照组更低(P<0.05),症状完全消失时间[(4.91±0.74)d vs.(6.62±1.02)d,t=7.308]、胃肠功能恢复正常时间[(7.75±0.96)d vs.(8.94±1.37)d,t=3.831]较对照组更短(P<0.05)。治疗后,观察组中治愈、好转和未愈的患者比例分别为55.17%(16/29)、37.93%(11/29)和6.90%(2/29)。对照组中治愈、好转和未愈的患者比例分别为44.83%(13/29)、27.59%(8/29)和27.59%(8/29)。观察组的治疗有效率高于对照组(χ^(2)=4.350,P<0.05)。观察组患者的不良反应率[10.34%(3/29)]与对照组的17.24%(5/29)相比,差异不显著(χ^(2)=0.580,P>0.05)。结论 UC患者接受美沙拉嗪口服联合灌肠治疗后,临床症状可以得到快速、有效的改善,胃肠功能能够得到良好的恢复。

Objective To investigate the application effect of oral mesalazine combined with enema in the clinical treatment of ulcerative colitis(UC). Methods 58 UC patients were randomly divided into observation group(oral mesalazine combined with enema treatment) and control group(oral mesalazine treatment), 29 cases in each group. Serum inflammatory factor levels and symptom improvement before and after treatment in the two groups were observed., compared with the recovery effect of its treatment. Results Compared with before treatment, the levels of serum inflammatory factors such as C-reactive protein(CRP) and tumor necrosis factor alpha(TNF-α) in two group patients after treatment were significantly decreased(P<0.05). CRP level [(6.51±0.43) mg/L vs.(7.74±0.57) mg/L, t=9.277], TNF-α level [(0.24±0.09) μg/L vs.(0.37±0.13)μg/L, t=4.428] in the observation group were significantly lower than those in the control group(P<0.05), the time for complete symptom disappearance [(4.91±0.74) days vs.(6.62±1.02) days, t=7.308], the time for gastrointestinal function to return to normal [(7.75±0.96)days vs.(8.94±1.37) days, t=3.831] in the observation group were significantly shorter than those in the control group(P<0.05). After oral mesalamine combined with enema treatment, the proportions of cured, improved and unhealed patients in the observation group were 55.17%(16/29), 37.93%(11/29) and 6.90%(2/29), respectively. After oral mesalamine treatment, the proportions of cured, improved and unhealed patients in the control group were 44.83%(13/29), 27.59%(8/29) and 27.59%(8/29), respectively. The treatment effective rate of the observation group was higher than that of the control group(χ^(2)=4.350, P<0.05). The adverse reaction rate of patients in the observation group [10.34%(3/29)] was not significantly different from 17.24%(5/29) in the control group(χ^(2)=0.580, P>0.05). Conclusion After receiving oral mesalazine combined with enema in UC patients, the clinical symptoms can be rapidly and effectively improved, and the gastrointestinal function can be recovered well.